Immunome, Inc. · NASDAQ:IMNM

Immunome — 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

14 slides from Immunome's conference presentation, Jun 2, 2026

  1. Slide 1: RINGSIDE: Phase 3 trial of varegacestat for progressing desmoid tumors

    RINGSIDE: A phase 3 randomized, placebo- controlled trial of varegacestat for treatment of progressing desmoid tumors Mrinal Gounder, MD Memorial Sloan Kettering Cancer Center Presented at: 2026 American Society of Clinical Oncology (ASCO) Annual Meeting | May 29 – June 2, 2026 | Chicago, Illinois,

  2. Slide 2: Key Takeaway Points

    Key Takeaway Points 1 2 3 The RINGSIDE Phase 3 Once-daily varegacestat Varegacestat has the study of varegacestat was generally well tolerated potential to address a need showed clinically with a manageable safety in patients with desmoid meaningful and significant profile consistent with the tumors

  3. Slide 3: Background

    Background • Desmoid tumors (DT) are rare, connective tissue tumors that are often locally aggressive and infiltrative • Targeted systemic therapies, including gamma-secretase inhibitors (GSIs, nirogacestat) and tyrosine kinase inhibitors (TKIs, sorafenib), are utilized for the treatment of DT1 • Th

  4. Slide 4: RINGSIDE Phase 3 Trial design (NCT04871282)

    RINGSIDE Phase 3 Trial (NCT04871282) Endpoints Key Eligibility Criteria Primary: PFS by BICR • Adults with histologically Varegacestat 1.2 mg PO once daily confirmed DT that has Varegacestat 1.2 mg Key Secondary: Open Label Extension (OLE)* progressed in the past 12 PO once daily (n=79) • ORR by BIC

  5. Slide 5: RINGSIDE Demographics

    RINGSIDE Demographics Characteristic, n (%) Varegacestat (n=79) Placebo (n=77) Median age (range), years 42.0 (18–66) 39.0 (20–69) Male 26 (32.9) 29 (37.7) Sex Female 53 (67.1) 48 (62.3) → Premenopausal 36 (45.6) 38 (49.4) Extra-abdominal 60 (75.9) 49 (63.6) Target tumor location† Intra-abdominal 19

  6. Slide 6: Varegacestat Demonstrated Significant Improvement in PFS

    Varegacestat Demonstrated Significant Improvement in PFS 84% reduction in the risk of radiographic disease progression or death with varegacestat vs. placebo Varegacestat No. of No. of Median PFS Placebo Patients Events (95% CI) (mo) Varegacestat 79 7 NE (NE, NE) Placebo 77 29 24.87 (13.80, NE) Haza

  7. Slide 7: Consistent PFS Benefit with Varegacestat Across Subgroups

    Consistent PFS Benefit with Varegacestat Across Subgroups Favors varegacestat Favors placebo Male Gender Female ≤ 30 years* Age > 30 years Intra-abdominal Tumor location Extra-abdominal APC mutation Yes S45F+S45P CTNNB1 mutation* T41A > 10cm* Baseline tumor size ≤ 10 cm WPI ≥ 2* Baseline pain score

  8. Slide 8: Significant Improvement in ORR with Varegacestat

    Significant Improvement in ORR with Varegacestat 100 Varegacestat Placebo Varegacestat (n=79) (n=77) ORR: 55.7% 50 Percent change Objective response rate, 44 (55.7) 7 (9.1) +20% n (%) [95% CI] [44.1, 66.9] [3.7, 17.8] 0 P < 0.0001 Time to objective response (months), 8.2 16.7 -30% 50 median (range)

  9. Slide 9: RINGSIDE Duration of Treatment and Response

    RINGSIDE Duration of Treatment and Response Earlier time to response with varegacestat compared with placebo ◼ Complete Response ◼ Partial Response ◼ Stable Disease Patients Patients ◼ Progressive Disease ◼ Not evaluable Varegacestat Placebo ⚫ First response ► Ongoing  Progression 2 4 6 8 10 12 14

  10. Slide 10: Significant Tumor Volume Reduction at Week 24 with Varegacestat

    Significant Tumor Volume Reduction at Week 24 with Varegacestat Change in Tumor Volume at Week 24 (cm3)* 150 Varegacestat • Varegacestat: -109.6 (40.64) 100 Median best percent change: Percent change −83% (range: −100 to 55) • Placebo +122.8 (42.72) 50 • Difference: −232.4 (57.39), P<0.0001 0 50 Pla

  11. Slide 11: Significant Improvement in Worst Pain Intensity at Week 12

    Significant Improvement in Worst Pain Intensity at Week 12 with Varegacestat Change in Worst Pain Intensity Score at Week 12* Change in Worst Pain Intensity Score Placebo Worsening • Varegacestat: −2.24 (0.27) • Placebo: +0.18 (0.27) • Difference: −2.42 (0.37), P<0.0001 • Clinically significant diff

  12. Slide 12: RINGSIDE Safety Profile

    RINGSIDE Safety Profile Varegacestat Placebo (n=79) (n=77) Adverse Events, n (%) Any grade Grade 3+ Any grade Grade 3+ • Among the most common Any adverse event 79 (100) 45 (57) 70 (91) 13 (17) adverse events, very few Reported in ≥25% in either arm* were Grade 3+ (table) Diarrhea 65 (82) 8 (10.1) 2

  13. Slide 13: Exposure, Dose Reduction, and Discontinuation

    Exposure, Dose Reduction, and Discontinuation Median Exposure: Ovarian Toxicity* • Varegacestat 20 months | Placebo 11 months • A known class effect of GSI Dose Reduction Due to AEs: • Varegacestat 56% | Placebo 5% • Varegacestat 80% | Placebo 9% (of premenopausal women) • Resolved in 55% of those w

  14. Slide 14: Conclusions

    Conclusions • The RINGSIDE Phase 3 study of varegacestat 1.2 mg once daily vs. placebo in progressing DT met its primary and all alpha-controlled secondary endpoints • Varegacestat benefits vs placebo: ▪ 84% reduction in the risk of a PFS event ▪ 55.7% ORR ▪ Significant reduction in tumor volume at

Immunome — 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on 6ix